Articles

Find an Article

Filter articles

Showing 1 to 10 of 564 results

LSIPR 50 2018: Raymond Chen and Kathleen O’Malley

US20-07-2018

Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Scott Gottlieb

US19-07-2018

Scott Gottlieb was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Aram Adourian—The entrepreneurial bug

US18-07-2018

At Flagship Pioneering, Aram Adourian, partner, knowledge management, uses his skills to leverage internal and external knowledge and informatics across the breadth of the company’s research activities, as he tells LSIPR.

LSIPR 50 2018: Josh Makower—Backing the innovators

US17-07-2018

Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.

The future of precision medicine part 2: data is king

International, UK17-07-2018Daniel Lim

In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Allen & Overy reports.

LSIPR 50 2018: James Flynn—An agent of change in healthcare

US16-07-2018

Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

EPO13-07-2018Jakob Wested, Timo Minssen, Esther van Zimmeren

As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.

LSIPR 50 2018: Paul Golian—Personalised medicine: the way forward

US13-07-2018

BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

Searching for variant sequences with pinpoint accuracy

12-07-2018Ellen Sherin 

The world of sequence variation IP is complicated and confusing, and fraught with legal risk, but there is a solution, as Ellen Sherin of GQ Life Sciences reports.

LSIPR 50 2018: Scott Alban—AstraZeneca

US12-07-2018

Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.

Showing 1 to 10 of 564 results

LSIPR